New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer - PubMed (original) (raw)

Review

New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer

Patrick M Forde et al. Clin Cancer Res. 2014.

Abstract

Recent discoveries that non-small cell lung cancer (NSCLC) can be divided into molecular subtypes based on the presence or absence of driver mutations have revolutionized the treatment of many patients with advanced disease. However, despite these advances, a majority of patients are still dependent on modestly effective cytotoxic chemotherapy to provide disease control and prolonged survival. In this article, we review the current status of attempts to target the epigenome, heritable modifications of DNA, histones, and chromatin that may act to modulate gene expression independently of DNA coding alterations, in NSCLC and the potential for combinatorial and sequential treatment strategies.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

J.R. Brahmer reports receiving commercial research grants from ArQuele, Bristol-Myers Squibb, and MedImmune and is a consultant/advisory board member for Bristol-Myers Squibb (uncompensated), MedImmune, and Merck. R.J. Kelly is a consultant/advisory board member for Novartis. No potential conflicts of interest were disclosed by the other author.

Figures

Figure 1

Concurrent widespread changes in gene expression with epigenetic therapy. EMT, epithelial–mesenchymal transition. Reprinted with permission from Azad et al. (44).

Cited by

Elevated origin recognition complex subunit 6 expression promotes non-small cell lung cancer cell growth.
Sang YH, Luo CY, Huang BT, Wu S, Shu J, Lan CG, Zhang F. Sang YH, et al. Cell Death Dis. 2024 Sep 30;15(9):700. doi: 10.1038/s41419-024-07081-y. Cell Death Dis. 2024. PMID: 39349930 Free PMC article.
KiSS-1 Modulation by Epigenetic Agents Improves the Cisplatin Sensitivity of Lung Cancer Cells.
Beretta GL, Alampi D, Corno C, Carenini N, Corna E, Perego P. Beretta GL, et al. Int J Mol Sci. 2024 May 6;25(9):5048. doi: 10.3390/ijms25095048. Int J Mol Sci. 2024. PMID: 38732265 Free PMC article.
The mitochondrial protein YME1 Like 1 is important for non-small cell lung cancer cell growth.
Xia Y, He C, Hu Z, Wu Z, Hui Y, Liu YY, Mu C, Zha J. Xia Y, et al. Int J Biol Sci. 2023 Mar 21;19(6):1778-1790. doi: 10.7150/ijbs.82217. eCollection 2023. Int J Biol Sci. 2023. PMID: 37063426 Free PMC article.
An Overview of DNA Methylation Indicators for the Course of Oral Precancer.
Wang W, Li W, Zhang H. Wang W, et al. Appl Bionics Biomech. 2022 Aug 26;2022:6468773. doi: 10.1155/2022/6468773. eCollection 2022. Appl Bionics Biomech. 2022. PMID: 36060560 Free PMC article. Retracted. Review.
An mTOR and DNA-PK dual inhibitor CC-115 hinders non-small cell lung cancer cell growth.
Chen F, Zhao H, Li C, Li P, Zhang Q. Chen F, et al. Cell Death Discov. 2022 Jun 18;8(1):293. doi: 10.1038/s41420-022-01082-6. Cell Death Discov. 2022. PMID: 35717530 Free PMC article.

References

1. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–42. - PubMed
1. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94. - PubMed
1. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150:1121–34. - PMC - PubMed
1. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31:2895–902. - PubMed
1. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51. - PubMed

New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer - PubMed (original) (raw)